Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 22%
Hold 50%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings has demonstrated a strong turnaround in its business, evidenced by reported 11.3% growth in technology and surgical products, primarily driven by robust Rosa placements and effective mergers and acquisitions. The company has outperformed peer growth rates over multiple quarters, supported by a healthy balance sheet and favorable conditions in the orthopedic market. Additionally, the knee segment showcased a solid growth rate of 5.3% globally, reflecting successful product penetration and adoption strategies.

Bears say

Zimmer Biomet Holdings is facing significant challenges as evidenced by its anticipated flat average selling prices (ASP) in FY25 and modest growth headwinds due to selling day differences. The company's growth estimates have been revised downward, with projected FY26 revenue growth at only 5.4% year-over-year and organic growth at a mere 3.1%, highlighting underperformance relative to peers in key segments. Additionally, the firm is grappling with execution difficulties, market share losses, and risks associated with its manufacturing processes, which collectively warrant a discount in valuation compared to its competitors.

ZBH has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 22% recommend Buy, 50% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 18 analysts, ZBH has a Hold consensus rating as of Feb 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.